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Introduction: Thymic carcinomas and thymic neuroendocrine 
tumors are rare diseases often treated with surgical resection. 
Currently, there are no guidelines regarding nodal dissection at the 
time of tumor resection. Moreover, the prognostic signiﬁcance of 
nodal metastases is unclear. The goal of this study was to deﬁne the 
incidence and prognostic relevance of nodal metastases in patients 
with thymic carcinoma and thymic neuroendocrine tumors.
Methods: The Surveillance, Epidemiology and End Results database 
was queried for patients who underwent surgical resection of thy-
mic carcinoma or a thymic neuroendocrine tumor with documented 
pathological examination of lymph nodes. The incidence of nodal 
metastases and the impact on survival were examined.
Results: We identiﬁed 176 patients with thymic carcinoma and 53 
with thymic neuroendocrine tumors. A median of three lymph nodes 
was sampled per patient. Positive metastasis to at least one lymph node 
was identiﬁed in 92 patients (40.2%). Nodal metastasis was more com-
mon in patients with thymic neuroendocrine tumors than in patients 
with thymic carcinoma (62.3% versus 33.5%). In multivariate analysis, 
nodal metastasis was more likely in patients with thymic neuroendo-
crine tumors and with more advanced tumors. The presence of nodal 
metastases had signiﬁcant, independent, adverse impact on survival 
(hazard ratio, 2.933, 95% conﬁdence interval, 1.903–4.521, p = 0.001). 
Median survival was 47 months in patients with nodal metastasis and 
124 months in patients without nodal metastases (p < 0.001). 
Conclusions: Nodal status seems to be an important prognostic fac-
tor in patients with thymic carcinoma and thymic neuroendocrine 
tumors. Nodal sampling should be performed during resection of 
these thymic malignancies.
Key Words: Thymic tumors, Thymic carcinoma, Thymic neuroendo-
crine tumors, Lymph node metastases, SEER registry.
(J Thorac Oncol. 2015;10: 1642–1647)
Thymic carcinomas used to be deﬁned by World Health Organization (WHO) classiﬁcations as a heterogeneous 
group of tumors that include adenocarcinoma of the thymus, 
squamous cell carcinoma of the thymus, and neuroendo-
crine tumors, among others.1 The recent WHO classiﬁcation2 
clearly distinguishes thymic carcinomas from thymic neuro-
endocrine tumors. Thymic carcinomas are very rare tumors, 
and historically, they have not been well studied because of the 
difﬁculty in acquiring sufﬁcient cases for analysis.3 We and 
others have retrospectively analyzed large databases to cir-
cumvent this limitation. We previously used the Surveillance, 
Epidemiology, and End Results (SEER) database to analyze 
prognostic variables in a cohort of 290 patients with thymic 
carcinoma.4 In early 2015, two large retrospective database 
studies were published that assessed stage at presentation, sur-
vival, and recurrence in patients with thymic carcinoma and 
thymic neuroendocrine tumors.5,6
Although most previous studies on thymic epithelial 
tumors easily deﬁned the tumor and metastases, very few 
studies have addressed the incidence and prognostic signiﬁ-
cance of the lymph nodal status in patients with thymic car-
cinoma or thymic neuroendocrine tumors. Our knowledge of 
nodal status in patients with thymic epithelial tumors comes 
mostly from a study by Kondo et al.,7 who compiled a data-
base of 1320 patients with thymic epithelial tumors including 
183 patients with thymic carcinoma and 40 patients with thy-
mic carcinoid tumors. The incidence of nodal metastases in 
these patients was 26.8% and 27.5%, respectively. A smaller 
study by Park et al.8 analyzed nodal metastases in 29 patients 
with thymic carcinoma who underwent nodal dissection and 
found that 20.8% of patients had pathologically conﬁrmed 
nodal metastases.
This study was designed to further deﬁne the incidence 
of nodal metastases in patients with thymic carcinoma and 
thymic neuroendocrine tumors and assess the prognostic sig-
niﬁcance of nodal metastases.
MATERIALS AND METHODS
Database and Query Criteria
The SEER database is sponsored by the National 
Cancer Institute and has been used to track cancer incidence 
and patient survival since 1973. The SEER database cur-
rently covers approximately 28% of the U.S. population and 
captures 98% of all cancer cases within the surveyed geo-
graphic areas. We used the SEER 18 Registry including the 
Hurricane Katrina Impacted Louisiana Cases for this analysis 
(SEER Program [www.seer.cancer.gov] SEER*Stat Database: 
Incidence—SEER 18 Regs Research Data + Hurricane Katrina 
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Impacted Louisiana Cases, November 2010 Sub [1973–2011 
varying], National Cancer Institute, Surveillance Research 
Program, Cancer Statistics Branch, released April 2014 based 
on the November 2013 submission). Speciﬁc ﬁelds for num-
ber of lymph nodes examined and number of positive nodes 
were created in 1988. SEER*Stat software (seer.cancer.gov/
seerstat) version 8.2.1 was used for data mining.
The SEER 18 database was queried for all cases of 
thymic carcinoma and thymic neuroendocrine tumors from 
January 1, 1988 to December 31, 2011 using the ICD-03 
codes 8002, 8010, 8012, 8013, 8020, 8021, 8070–8072, 
8074, 8140, 8240, 8243, 8246, 8586, 8588, and 8589. We 
included patients with the primary site labeled as C37.9 (thy-
mus). We further reﬁned the patient cohort to include only 
patients who had resection or debulking of the thymus, had 
at least one lymph node analyzed pathologically, and who 
survived for more than 30 days after resection. Patients with 
thymoma were not included in the analysis. Using available 
data, patients were staged according to the Masaoka-Koga 
classiﬁcation.9 Stage I (no transcapsular invasion) and stage 
IIa (microscopic transcapsular invasion) could not be differen-
tiated from one another using the available data and were ana-
lyzed together. The University of Tennessee Health Science 
Center Institutional Review Board approved this study, and 
the requirement for informed consent was waived.
Statistical Analysis
Continuous data variables were analyzed using 
Student’s t test. Nominal data were analyzed using crosstabs 
and Pearson’s χ2 test. To identify variables that could predict 
the presence of nodal metastases, univariate binary logistic 
regression was performed, followed by a multivariate analysis 
including only variables that had a p value less than 0.10 in the 
univariate analysis. Kaplan–Meier survival curves were con-
structed and compared using the log-rank test. To assess vari-
ables that impacted overall survival, univariate analysis was 
performed using the Cox univariate model and calculating the 
hazard ratio and 95% conﬁdence interval. Multivariate analy-
sis was performed using a Cox proportional hazard model, 
again including only variables that had a p value less than 
0.10 in univariate analysis. The proportionality of hazards was 
evaluated using Cox regression analysis with time-dependent 
covariables. The assumption of proportionality of hazards 
was tested and was not broken in any of the Cox regression 
models. Statistical analysis was performed with SPSS statisti-
cal software package version 21.0 (SPSS inc., Chicago, IL). 
Signiﬁcance was set at p value less than 0.05.
RESULTS
We identiﬁed 229 patients in the SEER database eligible 
for this analysis (Table 1). The majority of patients were male 
(56.8%) and white (79.0%) with a median age of 59 years 
(range 47–70 years). There were 176 patients (76.9%) with 
thymic carcinoma and 53 (23.1%) with thymic neuroendo-
crine tumors. Excluding the upstaging from nodal sampling, 
there were 62 (27.1%) classiﬁed as Masaoka-Koga stage I/
IIA; 25 (10.9%) classiﬁed as stage IIB; 120 (52.4%) as stage 
III; and 20 (8.8%) as stage IV. There were two (0.8%) patients 
who could not be staged without the nodal sampling. The 
median number of lymph nodes sampled per patient was three 
(median, 6; interquartile range [IQR], 1–43) and did not dif-
fer between patients with nodal metastasis (node positive) 
and patients without nodal metastasis (node negative). There 
were also no difference in number of sampled nodes between 
patients with thymic carcinoma and thymic neuroendocrine 
tumors (p = 0.590). Positive metastasis in at least one lymph 
node was identiﬁed in 92 patients (40.2%), and node-positive 
patients had a median of one positive node (IQR, 1–26).
There were a higher proportion of node-positive 
patients with thymic neuroendocrine tumors than with thymic 
carcinoma. Nodal metastasis was present in 33 of 53 patients 
(62.3%) with thymic neuroendocrine tumors when compared 
with only 59 of 176 patients (33.5%) with thymic carcinoma 
(p < 0.001). Similarly, patients with thymic neuroendocrine 
tumors had a signiﬁcantly more positive nodes per patient 
(median, 2; IQR, 1–26) than patients with thymic carcinoma 
(median, 1; IQR, 1–9, p = 0.031). There were no signiﬁcant 
differences in surgical treatment or radiation therapy between 
node-positive and node-negative patients (Table 1).
Identiﬁcation of positive nodes resulted in signiﬁcant 
changes to Masaoka-Koga staging that could be evaluated in 






n (%) 229 (100) 137 (59.8) 92 (40.2)
Sex, n (%) 0.122
  Male 130 (56.8) 73 (53.3) 57 (62.0)
  Female 99 (43.2) 64 (46.7) 35 (38.0)
Median age, yr (IQR) 59 (48, 69) 58 (49, 68) 59 (47, 70) 0.415
White, n (%) 181 (79.0) 102 (75.0) 79 (85.9) 0.066
Tumor type, n (%) <0.001
  Thymic carcinoma 176 (76.9) 117 (85.4) 59 (64.1)
  Neuroendocrine tumor 53 (23.1) 20 (14.6) 33 (35.9)
Tumor size, mm (IQR) 67 (48, 90) 65 (48, 86) 70 (49, 100) 0.069
Masaoka-Koga stage, n (%) <0.001
  Stage I/IIA 46 (20.1) 46 (33.6) 0
  Stage IIB 16 (7.0) 16 (11.7) 0
  Stage III 68 (29.7) 68 (49.6) 0
  Stage IV 98 (42.8) 6 (4.4) 92 (100)a
  Stage unknown 1 (0.4) 1 (0.7)
Lymph nodes analyzed,  
median (IQR)
3 (1, 6) 2 (1, 6) 4 (1, 7) 0.338
Surgery, n (%) 0.436
  Resection 213 (93.0) 129 (94.2) 84 (91.3)
  Debulking 16 (7.0) 8 (5.8) 8 (8.3)
Radiation therapy, n (%) 0.299
  Preoperative 14 (6.1) 8 (5.8) 6 (6.5)
  Postoperative 126 (55.0) 69 (50.4) 57 (62.0)
  None 86 (37.6) 57 (41.6) 29 (31.5)
  Unknown 3 (1.3) 3 (2.2) 0 (0)
aBy deﬁnition the presence of positive lymph nodes dictates classiﬁcation as 
stage IV.
IQR, interquartile range.
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91 patients. The sampling of lymph nodes and the presence of 
positive nodes effectively upstaged 77 of 91 patients (84.6%) 
previously staged as I to III to stage IV. Discounting the posi-
tive nodes, 16 of 91 patients (17.6%) would have been clas-
siﬁed as Masaoka-Koga stage I/IIA, 9 of 91 (9.9%) as IIB, 
and 52 of 91 (57.1%) would have been classiﬁed as stage III. 
Fourteen patients (14/91, 15.4%) were already classiﬁed as 
stage IV and were not upstaged as a result of ﬁnding a positive 
lymph node.
Prognostic Factors for Lymph Node Metastasis
In univariate analysis, the presence of nodal metasta-
ses was more likely in non-whites (p = 0.049), in patients 
with thymic neuroendocrine tumors (p < 0.001), and 
in patients with a more advanced local tumor based on 
Masaoka-Koga classiﬁcation that was determined without 
knowledge of the presence of nodal metastases (p = 0.001; 
Table 2). Multivariate analysis revealed that patients with 
thymic neuroendocrine tumors (p = 0.001) and patients with 
more locally advanced tumors (p = 0.001) had signiﬁcantly 
higher likelihood of developing nodal metastases (Table 3). 
Patients with thymic neuroendocrine tumors were 3.5 times 
more likely to develop nodal metastases than patients with 
thymic carcinoma. Patients with tumors invading adjacent 
organs were 2.6 times more likely to have nodal metastases 
when compared with patients with stage I/IIA tumors, and 
patients with tumors classiﬁed as stage IV based on criteria 
other than nodal status were 6.7 times more likely to have 
nodal metastases (Table 3).
Survival
Overall median survival in the entire cohort was 103 
months (95% conﬁdence interval, 73.6–132.4). There was no 
signiﬁcant difference in survival between patients with thymic 
carcinoma and patients with thymic neuroendocrine tumors 
(117 versus 85 months, p = 0.794; Fig. 1A). Surgical debulk-
ing was performed in 16 of 229 patients (7.0%), and resection 
of the thymus and the tumor was performed in 213 of 229 
patients (93.0%). Survival was signiﬁcantly worst in patients 
who underwent debulking when compared with patients 
who underwent resection (41 versus 109 months, p = 0.017). 
Node-negative patients had better survival than node-positive 
patients (124 versus 47 months, p < 0.001; Fig. 1B). Data on 
neoadjuvant and adjuvant radiation therapy were available for 
all node-positive patients. Radiation therapy was administered 
before surgery in 6 of 92 node-positive patients (6.5%) and 
after surgery in 57 of 92 (62.0%). Radiation was not admin-
istered to 29 of 92 node-positive patients (31.5%). Median 
survival in patients who received preoperative radiation was 
60 months, 42 months in patients who received postoperative 
radiation, and 68 months in patients who did not receive radia-
tion (p = 0.618).
In univariate analysis, type of surgery (resection versus 
debulking, p = 0.020), Masaoka-Koga stage (p < 0.001), and 
the presence of positive lymph nodes (p < 0.001) were signiﬁ-
cant factors affecting survival (Table 4). Because Masaoka-
Koga stage and positive lymph nodes are strong covariables 
(all patients with positive lymph nodes are by deﬁnition 
Masaoka-Koga stage IV), we constructed two Cox models 
for multivariate analysis (Table 5). The ﬁrst model included 
Masaoka-Koga stage, and the second model included nodal 
status. In the ﬁrst model, type of surgery and Masaoka-Koga 
stage signiﬁcantly affected survival. In the second model, type 
of surgery and the presence of positive nodes signiﬁcantly 
affected survival.
DISCUSSION
This analysis of lymph node metastases in 229 patients 
with thymic carcinoma or thymic neuroendocrine tumors 
yielded several relevant ﬁndings. First, the presence of nodal 
metastases is an important prognostic factor in these patients, 
increasing the risk of death by approximately threefold. 
Second, nodal metastases are more likely in patients with thy-
mic neuroendocrine tumors or more advanced tumors. Third, 
the presence of nodal metastases, identiﬁed by nodal sampling, 
changed the Masaoka-Koga staging of 84% of patients who 
would not have been classiﬁed as stage IV otherwise. Finally, 
type of surgery performed is a signiﬁcant factor affecting sur-
vival and patients who underwent debulking rather than resec-
tion fare worse.
TABLE 2. Univariate Analysis of Factors Affecting Nodal 
Metastases
Variable HR (95% CI) P
Sex (male vs. female) 1.428 (0.833–2.446) 0.195
Age at diagnosisa 0.992 (0.974–1.011) 0.414
Race (white vs. others) 0.494 (0.244–0.998) 0.049
Histology (thymic carcinoma vs. NETT) 3.272 (1.730–6.190) <0.001
Tumor gradeb 1.349 (0.849–2.146) 0.205
Tumor sizea 1.007 (0.999–1.015) 0.072
Number of lymph nodes examined 1.023 (0.976–1.072) 0.340
Masaoka-Kogac 1.641 (1.227–2.195) 0.001
aAnalyzed as a continuous variable.
bTumor grade deﬁned by SEER as well differentiated, moderately differentiated, 
poorly differentiated, and anaplastic.
cExcluding the presence of nodal metastases.
CI, conﬁdence interval; HR, hazard ratio; NETT, thymic neuroendocrine tumors/
neuroendocrine thymic tumors; SEER, Surveillance, Epidemiology, and End Results.
TABLE 3. Multivariate Analysis of Factors Affecting Nodal 
Metastases
Variable HR (95% CI) P
Race (white vs. others) 0.576 (0.260–1.277) 0.175
Histology (thymic carcinoma vs. NETT) 3.582 (1.744–7.357) 0.001
Tumor sizea 1.004 (0.995–1.013) 0.393
Masaoka-Koga stageb
  Stage IIB vs. I/IIA 1.436 (0.459–4.497) 0.534
  Stage III vs. I/IIA 2.660 (1.212–5.835) 0.015
  Stage IV vs. I/IIA 6.775 (2.026–22.651) 0.002
aAnalyzed as continuous variable.
bMasaoka-Koga stage as determined without examination of nodal status.
CI, conﬁdence interval; HR, hazard ratio; NETT, thymic neuroendocrine tumors/ 
neuroendocrine thymic tumors.
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Although the International Thymic Malignancy Group 
(ITMIG) and the International Association for the Study of 
Lung Cancer have proposed a new tumor, node, metastasis 
(TNM) classiﬁcation for thymic malignancy that incorpo-
rates nodal status, data on nodal metastases in patients with 
thymic malignancies are sparse.10,11 Only two previous pub-
lications have addressed nodal status in patients with thymic 
malignancies, and two recent, large database studies did not 
address the nodal status of patients with thymic carcinoma or 
thymic neuroendocrine tumors.5–8 Kondo et al.7 sent a ques-
tionnaire to 185 Japanese centers and compiled a database 
of 1320 patients with thymic malignancies.7 There were 183 
cases of thymic carcinoma and 40 cases of thymic carcinoid 
tumors. The incidence of nodal metastases in patients with 
thymic carcinoma was 26.8%, and it was 27.5% in patients 
with thymic carcinoid tumors. Park et al.,8 in a retrospective 
review of 37 patients with thymic carcinoma (29 underwent 
nodal dissection), found a 20% incidence of nodal metasta-
ses. The incidence of metastases is lower in these studies than 
in our study—33% incidence of nodal metastases in patients 
with thymic carcinoma and 62.5% in patients with thymic 
neuroendocrine tumors. There are several possible reasons for 
this difference. We included patients with all types of neu-
roendocrine thymic tumors including patients with large-cell 
neuroendocrine carcinoma, neuroendocrine carcinoma, and 
malignant carcinoid tumors, which may be more prone to 
metastases. It is unclear whether the whole spectra of thymic 
neuroendocrine tumors were included in Kondo et al.’s study.7 
In addition, we included patients who underwent debulking, 
which may account for the higher incidence of nodal metasta-
ses. Park et al.8 excluded patients who underwent incomplete 
resection.
The 2004 WHO publication on tumors of the lung, 
pleura, thymus, and heart classiﬁed thymic carcinoma and 
FIGURE 1. A, Kaplan–Meier survival curve of patients with thymic carcinoma and thymic neuroendocrine tumors. NETT, 
 thymic neuroendocrine tumors/neuroendocrine thymic tumors. B, Kaplan–Meier survival curve of patients without and with 
nodal metastases.
TABLE 4. Univariate Analysis of Factors Affecting Survival
Variable HR (95% CI) P
Sex (male vs. female) 0.985 (0.645–1.506) 0.946
Age at diagnosisa 1.002 (0.986–1.017) 0.849
Race (White vs. others) 1.021 (0.580–1.797) 0.942
Tumor (Thymic carcinoma vs. NETT) 1.066 (0.660–1.720) 0.795
Tumor gradeb 0.940 (0.689–1.283) 0.698
Tumor sizea 1.001 (0.996–1.007) 0.651
Number of lymph nodes examineda 0.994 (0.952–1.039) 0.799
Surgery (resection vs. debulking) 0.455 (0.234–0.884) 0.020
Masaoka-Koga stage
  I/IIA vs. IV 0.177 (0.086–0.363) <0.001
  IIB vs. IV 0.360 (0.130–1.00) 0.050
  III vs. IV 0.462 (0.280–0.764) 0.003
Positive lymph nodes (yes vs. no) 2.910 (1.892–4.476) <0.001
Radiation therapy (yes vs. no) 1.122 (0.716–1.758) 0.616
aAnalyzed as continuous variable.
bTumor grade deﬁned by SEER as well differentiated, moderately differentiated, 
poorly differentiated, and anaplastic.
CI, conﬁdence interval; HR, hazard ratio; NETT, thymic neuroendocrine tumors/
neuroendocrine thymic tumors; SEER, Surveillance, Epidemiology, and End Results.
TABLE 5. Multivariate Analysis of Factors Affecting Survival
Variable HR (95% CI) P
Model 1
  Surgery (resection vs. debulking) 2.277 (1.160–4.472) 0.017
Masaoka-Koga stage
  Masaoka-Koga stage I/IIA vs. IV 0.172 (0.083–0.355) <0.001
  Masaoka-Koga stage IIB vs. IV 0.384 (0.138–1.070) 0.067
  Masaoka-Koga stage III vs. IV 0.456 (0.276–0.753) 0.002
Model 2
  Surgery (resection vs. debulking) 2.237 (1.147–4.364) 0.018
  Positive lymph nodes (yes vs. no) 2.933 (1.903–4.521) <0.001
CI, conﬁdence interval; HR, hazard ratio.
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thymic neuroendocrine tumors in a single category, differ-
entiating both from thymoma.1 It is unclear if both diseases 
should be classiﬁed together or if the natural history of thymic 
carcinoma and thymic neuroendocrine tumors is similar. The 
latest and recent WHO classiﬁcation2 clearly distinguishes 
thymic carcinoma from thymic neuroendocrine tumors rec-
ognizing the signiﬁcant differences between the two patholo-
gies. Although our study did not reveal a difference in survival 
between these two thymic tumor types, it did show a signiﬁ-
cant difference in the risk of nodal metastases. Patients with 
thymic neuroendocrine tumors had an approximately three 
times higher risk of nodal metastases when compared with 
patients with thymic carcinoma.
Another important ﬁnding in our study is the potential 
for nodal metastatic disease even in tumors classiﬁed as a rela-
tively early stage by other criteria. We found that without nodal 
sampling, 25 of 91 patients (27.5%) would have been staged as 
Masaoka-Koga stage I or II, and 52 of 91 (57.1%) would have been 
classiﬁed as stage III. In total, 84.6% of patients were upstaged 
from lower stages as a result of node-positive status. This is very 
similar to our ﬁndings in patients with thymoma in whom the 
ﬁnding of nodal metastases upstaged 80% of patients with nodal 
metastases. Although ours is a selected population that may over-
estimate the incidence of metastases, our ﬁndings underscore the 
need for some nodal sampling as an integral part of surgical treat-
ment of thymic carcinomas and thymic neuroendocrine tumors. 
This may require a change in practice for many surgeons. The 
advent of minimally invasive techniques has popularized unilat-
eral thymectomies, which do not allow sampling of both sides of 
the chest. A new staging proposal, put forth by the ITMIG and 
International Association for the Study of Lung Cancer, classiﬁes 
anterior mediastinal nodes as N1 and deep compartment nodes 
as N2.10,12 Because of the central nature of most thymic tumors, 
N2 nodes may be involved bilaterally. Guidelines on sampling of 
lymph nodes during surgical treatment of thymic tumors are lack-
ing but are urgently needed. Until such guidelines are available, it 
is prudent to sample N1 and N2 nodes at least unilaterally when 
operating on thymic malignancies.
In recent large database studies by Filosso et al.6 and 
Ahmad et al.,5 patients with thymic neuroendocrine tumors 
had a median overall survival of 7.5 years, and patients with 
thymic carcinoma had median overall survival of 6.6 years. 
In our study, median overall survival for patients with thymic 
neuroendocrine tumors was 7.1 years, and median survival 
for patients with thymic carcinoma was 9.7 years. The differ-
ence in survival in patients with thymic carcinoma between 
our study and the study by Ahmad et al. 5 may be explained 
by the fact that Ahmad et al.’s series included some patients 
who did not have surgical therapy. Survival data were avail-
able on 836 patients, and surgery was performed on 733. In 
our previous study of patients with thymic carcinoma, patients 
who did not undergo surgery had a median overall survival of 
4 years; the median overall survival in patients who under-
went surgery was 8.7 years.4 As in other studies, incomplete 
resection was an adverse prognostic factor in patients with 
thymic carcinoma and thymic neuroendocrine tumors.4–6,13,14 
Although the SEER registry does not have a ﬁeld for R1 or 
R2 resection, we believe that debulking is a good surrogate 
for incomplete resection. As with thymoma, complete resec-
tion of thymic carcinoma and thymic neuroendocrine tumors 
is likely the most important aspect of treatment.
The role of neoadjuvant and adjuvant therapy in patients 
with thymic carcinoma and thymic neuroendocrine tumors 
is unclear. Using SEER data on thymic carcinoma, we were 
unable to demonstrate a signiﬁcant effect of adjuvant radiation 
therapy,4 but SEER does not contain information on chemo-
therapy. Ahmad et al.5 found that the use of any radiation ther-
apy had a positive impact on survival. Rufﬁni et al.14 analyzed 
a cohort of patients with thymic carcinoma from the European 
Society of Thoracic Surgeons database and found that adju-
vant therapy was beneﬁcial in improving overall survival. 
Filosso et al.6 did not ﬁnd neoadjuvant or adjuvant therapy 
useful in patients with thymic neuroendocrine tumors. The 
different ﬁndings underscore the fact that thymic carcinomas 
and thymic neuroendocrine tumor are different diseases and 
will respond differently to adjuvant therapy.
Studying uncommon diseases is challenging, and inves-
tigators often use large retrospective databases to assemble 
cohorts for analysis. Such databases, like the SEER registry, 
have signiﬁcant limitations and are constrained by their retro-
spective nature. Although broad in its reach, the SEER database 
is subjected to limited data points and potential reporting inac-
curacies. Our cohort is likely a selected one, and the contribut-
ing surgeons may have been more likely to sample nodes that 
were enlarged already. It is likely that the overall incidence of 
nodal metastases in thymic carcinoma and thymic neuroendo-
crine tumors is lower than that reported in our study. Another 
signiﬁcant shortcoming is the lack of a standardized pathology 
review. Pathology data are obtained from multiple centers with-
out standardization among the pathologists, and each patholo-
gist may have a different method of analyzing and identifying 
lymph nodes in the specimen. The SEER database also lacks 
information on chemotherapy, on the anatomical location of 
the dissected lymph nodes, and information on the surgical 
approach used (minimally invasive or traditional open surgery). 
Finally, the reporting of complete resection is somewhat subjec-
tive in the SEER database, and the reporting of complete thymic 
excision is not the same as an R0 resection in all cases. It is 
unclear how the fact that some patients may have had an incom-
plete resection might affect the results of our study.
In summary, nodal metastases from thymic carcinomas 
and thymic neuroendocrine tumors seem to be relatively com-
mon. Nodal metastases denote poorer prognosis, and routine 
nodal sampling should be incorporated into surgical treatment 
of thymic malignancy. It is unclear how this recommendation 
will affect practice patterns considering the increasing inci-
dence of minimally invasive and unilateral approaches to thy-
mic malignancies. Pathology specimens should be dissected 
meticulously to identify nodal tissue and potential metastases. 
The role of adjuvant radiation therapy is unclear, and in our 
cohort, it did not prolong survival. More studies are needed to 
properly clarify the incidence and impact of nodal metastases 
in patients with rare thymic tumors. The ITMIG thymic malig-
nancy prospective database may provide an excellent platform 
for future studies on thymic carcinoma and thymic neuroen-
docrine tumors.
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